IceCure Medical Announces Publication Of Independent Study Titled 'Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients' In British Journal of Radiology
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical Ltd. (NASDAQ: ICCM) announced the publication of an independent study in the British Journal of Radiology, which found that cryoablation is a safe and effective alternative to surgery for early-stage breast cancer. The study showed a 100% complete ablation rate for Luminal A and B breast cancer tumors ≤ 25mm after a median follow-up of 16 months.
August 14, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical's cryoablation technology demonstrated a 100% complete ablation rate for early-stage breast cancer tumors in a recent independent study, suggesting it is a safe and effective alternative to surgery.
The study's positive results highlight the effectiveness and safety of IceCure Medical's cryoablation technology, which could lead to increased adoption and market share. This is likely to positively impact the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100